Related Experiment Video
Updated: Mar 1, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
KML001 and doxercalciferol induce synergistic antileukemic effect in acute lymphoid leukemia cells
Yang Liu1, Dong-Yeop Shin1, Somi Oh1
1Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Abstract:
KML001 (NaAsO2, sodium metaarsenite, KOMINOX), a kind of arsenic compound, that has shown promising efficacy in non-Hodgkin's lymphoma (NHL) both in vitro and in vivo. In our study, the antileukemic effect of KML001 on acute lymphoid leukemia (ALL) and its mechanism of action were investigated. The results showed that KML001 inhibited cell proliferation in two types of ALL cell lines, CCRF-CEM and Molt-4. Exposure of ALL cells to KML001 induced apoptosis in a time-dependent manner. KML001 caused cell cycle arrest at G2/M phase instead of G0/G1 phase shown in other leukemia cells. In addition, we also tested the possibility of synergy of KML001 with doxercalciferol, a vitamin D2 derivative. Also, we found that a combination of KML001 with doxercalciferol showed a synergistic effect on ALL cell lines and this could be due to its different mechanism of action. Overall, our findings demonstrated KML001 could be a promising antileukemic agent especially when it is combined with doxercalciferol in ALL treatment.
Insights
Sodium metaarsenite (KML001) shows antileukemic effects against acute lymphoid leukemia (ALL) by inhibiting proliferation and inducing apoptosis. Combining KML001 with doxercalciferol enhances this effect, suggesting a promising therapeutic strategy for ALL.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Sodium metaarsenite (KML001) demonstrates efficacy in non-Hodgkin's lymphoma.
- Acute lymphoid leukemia (ALL) remains a significant challenge in hematologic malignancies.
Purpose of the Study:
- To investigate the antileukemic effects of KML001 on ALL cell lines.
- To elucidate the mechanism of action of KML001 in ALL.
- To evaluate the synergistic potential of KML001 with doxercalciferol in ALL treatment.
Main Methods:
- In vitro studies using ALL cell lines (CCRF-CEM, Molt-4).
- Assessment of cell proliferation, apoptosis, and cell cycle progression.
- Combination studies with doxercalciferol.
Main Results:
- KML001 significantly inhibited ALL cell proliferation.
- KML001 induced time-dependent apoptosis and G2/M cell cycle arrest in ALL cells.
- A synergistic antileukemic effect was observed when KML001 was combined with doxercalciferol.
Conclusions:
- KML001 exhibits potent antileukemic activity against ALL.
- The combination of KML001 and doxercalciferol presents a promising therapeutic strategy for ALL, potentially through distinct mechanisms of action.
